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Abstract
Cancer progresses through a series of histopathological stages. Progression is thought to be driven
by the accumulation of genetic alterations and consequently gene expression pattern changes. The
identification of genes and pathways involved will not only enhance our understanding of the
biology of this process, it will also provide new targets for early diagnosis and facilitate treatment
design. Genomic approaches have proven to be effective in detecting chromosomal alterations and
identifying genes disrupted in cancer. Gene expression profiling has led to the subclassification of
tumors. In this article, we will describe the current technologies used in cancer gene discovery, the
model systems used to validate the significance of the genes and pathways, and some of the genes
and pathways implicated in the progression of preneoplastic and early stage cancer.
Using genomic approaches to understand cancer 
progression
The accumulation of genetic alterations is thought to drive
the progression of normal cells through hyperplastic and
dysplastic stages to invasive cancer and, finally, metastatic
disease. Since the initial efforts to link histopathological
changes to the mutation of specific genes in colorectal
cancer [1], progression models have been developed for
many tumor types, including lung, breast, head and neck,
and prostate [2-5]. Mutational and gene expression analy-
sis of known tumor suppressors and oncogenes in the
context of early tumorigenesis has provided insight into
the role of these genes in cancer progression [6,7]. Gene
discovery has been greatly facilitated by molecular cytoge-
netic technologies identifying chromosomal regions asso-
ciated with various stages and outcomes. Furthermore,
high throughput, genome-wide approaches and the com-
plete sequencing of the human genome have accelerated
the large-scale discovery of cancer-related genes and path-
ways [8].
While genetic alterations in tumors are common, changes
found in premalignant stages are more likely to represent
causal events initiating and promoting cancer develop-
ment. These events may be masked by the complex pat-
tern of genetic alterations often associated with genetic
instability in later stages of disease. For this reason all
stages of progression have to be considered in order to
fully understand how malignant tissues develop. To date,
genomic and proteomic efforts have been primarily
directed at the study of tumors. The relatively limited lit-
erature on genetic studies of earlier stage cancers is attrib-
utable to challenges associated with accessing
premalignant specimens and the fact that genome-wide
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analysis would require quantities of material far exceeding
the size of the minute specimens obtained. Recent
advances in cell isolation techniques and miniaturization
of genomic technologies have enabled comprehensive
molecular profiling of selected cell types and high resolu-
tion mapping of gene disruption associated with specific
disease phenotypes. This review article describes the cur-
rent genomic technologies used for analysis of cancer, the
model systems used to corroborate the significance of can-
didate cancer genes and pathways, and the genetic pro-
gression models for common types of cancer.
Tissue heterogeneity
Tumors and precancerous lesions are heterogeneous cell
populations harboring normal stromal and inflammatory
cells. The presence of these cells could mask the detection
of genetic and gene expression alterations in the cancer
cells. The development of laser-assisted microdissection
techniques addresses this problem by enabling selective
isolation of cell populations, for example normal epithe-
lium and hyperplastic cells [9-11] (Fig. 1).
Three commonly used microdissection techniques are
laser capture microdissection (LCM), laser microbeam
microdissection (LMM), and laser pressure catapult (LPC)
[11]. LCM involves the capture of cells by adhering them
to a thermoplastic membrane activated by a near-infrared
low power laser [10]. The relatively low intensity of the
laser does not damage DNA, RNA, or proteins in the cap-
tured cells, while the remaining tissue section is left intact
on the glass slide [11]. LMM uses a focused laser beam to
cut out target cells and to photoablate unwanted adjacent
tissue [12]. LMM is often used in conjunction with LPC, a
technique that involves the build up of laser-generated
high-photon density under a given specimen, causing the
selected cells of interest to catapult up along the path of
the beam and become available for collection [13].
Identification of genetic alterations
Current methods for genome-wide detection of genetic
alterations fall into three main categories: (1) molecular
cytogenetic evaluation of chromosomal aberrations and
re-arrangements, (2) DNA polymorphism analysis for
detecting loss of heterozygosity (LOH) or allelic imbal-
ance, and (3) comparative genomic hybridization (CGH)
approaches for identifying segmental copy number
changes.
Molecular cytogenetics
Cytogenetic approaches are designed to detect aberrations
and rearrangements under direct examination of chromo-
somes and chromosomal targets. G-banding, fluorescence
in situ hybridization (FISH), and spectral karyotyping
(SKY) are the commonly used methods [14,15]. G-band-
ing is often used in clinical settings for the analysis of leu-
kaemia and is best suited to detect large chromosomal
aberrations, namely structural or numeric changes [16].
This method evaluates stained metaphase chromosome
spreads to identify rearrangements and gain or loss of
chromosome bands. One of the most comprehensive
databases of cytogenetic information for various tumor
types is the Mitelman Database of Chromosome Aberra-
tions in Cancer [17]. This and other cytogenetic databases
are listed in Table 1.
FISH has helped bridge the gap between molecular genet-
ics and classical cytogenetics. This technology uses specific
DNA probes of known chromosomal location to evaluate
alterations at a specific locus on a cell-by-cell basis (Fig
2a) [18]. Gain, loss, and splitting of hybridization signals
on metaphase or interphase chromosomes reflect duplica-
tion, deletion, and translocation events respectively [19].
FISH is useful in fine mapping genetic alterations in very
small specimens such as premalignant lesions since it
does not require microdissection. With the development
of fluorochromes that fluoresce at different wavelengths,
Laser capture microdissection of prostate tissue sections Figure 1
Laser capture microdissection of prostate tissue sec-
tions. Panel A shows hematoxylin & eosin (H&E) stained 
prostate section. Black arrow indicates stromal cells. Red 
arrows indicate epithelial cells. Panel B shows laser outline 
of the cells to be collected. Panel C shows the remaining 
cells after laser capture. Panel D shows the cells collected 
from the outlined area. Images provided by Dr. J R. Vielkind.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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Table 1: On-line Resources
1. Sequence Databases
Nucleotide Sequence http://www.ncbi.nlm.nih.gov/ NCBI – GenBank
http://www.ebi.ac.uk/embl.html EMBL-EBI – Nucleotide Sequence Database
http://www.ddbj.nig.ac.jp DNA Data Bank of Japan
Transcript http://www.ncbi.nlm.nih.gov/UniGene/ NCBI – UniGene
http://mcb.harvard.edu/gilbert/EID/ The Exon-Intron Database
http://www.ncbi.nlm.nih.gov/RefSeq/ NCBI – Reference Sequence
http://genome.ucsc.edu/ UC – Santa Cruz – Genome Bioinformatics
Protein http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=Protein
NCBI – Entrez-Protein
http://pir.georgetown.edu/ Protein Information Resource
http://www.expasy.org/sprot Swiss-Prot
http://www.expasy.org/prosite PROSITE
http://www.ebi.ac.uk/proteome/ EMBL-EBI – Proteome Analysis
http://www.expasy.org/ch2d/ Swiss-2DPAGE
2. Signalling Pathways
http://www.geneontology.org/ Gene Ontology Consortium
http://www.genome.ad.jp/kegg Kyoto Encyclopedia of Genes and Genomes
http://www.biocarta.com/ BioCarta
3. Human and non-human vertebrate genomes
http://www.tigr.org/tdb/tgi.shtml The Institute for Genomic Research Gene Indices
http://genome.ucsc.edu/ UC – Santa Cruz – Genome Bioinformatics
http://www.sanger.ac.uk/HGP/ The Sanger Institute: Human Genome Project
http://www.ensembl.org/ Ensembl Genome Browser
http://genome.wustl.edu/ Washington U St. Louis Genome Sequencing Center
http://www.ncbi.nlm.nih.gov/LocusLink NCBI – LocusLink
http://www.gdb.org/ The Genome Database
http://www.ncbi.nlm.nih.gov/SNP/ NCBI – Single Nucleotide Polymorphism database
http://www.genelynx.org GeneLynx
http://www.ncbi.nih.gov/IEB/Research/Acembly/
index.html
NCBI – Acembly/AceView
http://gai.nci.nih.gov/html-snp/imagemaps.html NCI-CGAP – Comprehensive SNP Imagemaps
http://www.informatics.jax.org/ Mouse Genome Informatics
http://rgd.mcw.edu/ Rat Genome Database
http://genome.jgi-psf.org/fugu6/fugu6.home.html Doe Joint Genome Institute (Fugu genome resource)
4. Human Genes and Diseases
http://Bioinfo.weizmann.ac.il/cards/ GeneCards™
http://www.ncbi.nlm.nih.gov/Omim/ NCBI – Online Mendelian Inheritance in Man
5. Microarray and Gene Expression Databases
SAGE http://www.sagenet.org/ SAGEnet
http://www.ncbi.nlm.nih.gov/SAGE/ NCBI – SAGEmap
http://cgap.nci.nih.gov/SAGE NCI-CGAP – SAGE Genie
Microarray http://www.ebi.ac.uk/arrayexpress EMBL-EBI – ArrayExpress
http://bodymap.ims.u-tokyo.ac.jp/ BODYMAP
http://hugeindex.org/ Human Gene Expression Index
http://genome-www5.stanford.edu Stanford Microarray Database
http://www.longhornarraydatabase.org/ Longhorn Array DatabaseMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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multicolor FISH (M-FISH) has enabled the examination
of multiple loci in the same experiment [20].
SKY uses 24 different probe sets to virtually paint each
chromosome a different color. This technique involves
the simultaneous excitation of multiple fluorochromes
and the use of an interferometer to determine the profile
at each pixel [15] (Fig 2b).
Although whole genome cytogenetic techniques are lim-
ited to the identification of intrachromosomal rearrange-
ments and breakpoint determination, they have been the
preferred techniques for detailed karyotypic assessment of
structural chromosome aberrations [15].
Assessing LOH using polymorphic markers
Microsatellite analysis uses simple sequence repeat (SSR)
polymorphisms as markers for detecting LOH. A polymer-
ase chain reaction (PCR) using primers flanking a repeat
should yield two signals corresponding to the two hetero-
zygous alleles. When the signal intensity ratio of the
tumor alleles differs from that of the normal alleles, allelic
imbalance or LOH is inferred. An example of mapping of
LOH at the chromosome scale was the use of 28 markers
spanning chromosome 3p to determine three distinct
regions of alteration in non-small cell lung cancer [21]. In
addition, microsatellite analysis is commonly used for
fine mapping minimal regions of LOH. However, this
approach is limited by the availability of polymorphic
SSR markers in the chromosomal regions of interest. For
microdissected, minute premalignant specimens, DNA
yield is an additional limitation since each marker
requires at least 5 nanograms of DNA per assay [22].
Therefore, although whole-genome allelotyping has been
applied to early stage cancer [23-26], efforts have been
largely focused on tumors and cell lines where material is
not limiting.
Single nucleotide polymorphisms (SNPs) are another
source of DNA markers used in identifying LOH. SNPs are
common in the human genome and in some instances
their variation can be correlated to disease behaviour
[27,28]. The through-put of this approach is greatly
enhanced by parallel analysis of multiple loci on microar-
rays. For example, GeneChip®  arrays from Affymetrix®
have enabled simultaneous tracking of approximately
1,500 SNPs [29]. The large number of SNPs examined
would compensate for the fact that not all loci will be
informative (heterozygous). The recently released "Map-
ping 10 K Array" tracks greater than 10,000 SNPs distrib-
uted throughout the genome should increase the
information content of an array hybridization
experiment.
Unlike microsatellite or SNP analyses, amplified fragment
length polymorphism (AFLP)-based approaches require
no previous knowledge of polymorphisms. Fingerprinting
techniques such as random amplification of polymorphic
DNA (RAPD) or arbitrarily primed PCR (AP-PCR) use
short primers of 10 to 20 nucleotides to amplify multiple
fragments randomly distributed throughout the genome
(Fig 3). The PCR products are then separated by electro-
phoresis to display up to dozens of anonymous DNA pol-
ymorphisms [30-32]. It has been applied to a variety of
tumor types to study genomic instability, identify novel
DNA amplifications and deletions, and to assess changes
in methylation state [33-42]. The recently developed
methylation-sensitive AFLP (MS-AFLP) technology allows
for an unbiased assessment of epigenetic changes in a sub-
set of methylation sites throughout the genome [43,44].
However, the use of RAPD patterns in predicting progno-
sis has not yet been widely used.
6. Cytogenetics
http://www.wiley.com/legacy/products/subject/life/
mitelman/
Mitelman's Catalog of Chromosome Aberrations in 
Cancer
http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi NCBI – SKY/M-FISH GH Database
http://amba.charite.de/cgh/ Charité – Comparative Genomic Hybridization
http://www.infobiogen.fr/services/chromcancer/ Atlas Chromosomes in Cancer
http://www.progenetix.net/ Progenetix – Online CGH Database
http://www.helsinki.fi/cmg/ Laboratory of Cytomolecular Genetics (CMG)
7. Molecular Cancer Sites
http://cgap.nci.nih.gov/ NCI-CGAP (Cancer Genome Anatomy Project)
The Tumor Gene Database
Table 1: On-line Resources (Continued)Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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Comparative genomic hybridization
Comparative Genomic Hybridization (CGH) detects seg-
mental DNA copy number changes. Differentially labeled
tumor DNA and control normal DNA are co-hybridized
to a metaphase chromosome spread, producing an aver-
age fluorescence ratio profile at approximately 20 Mbp
resolution [45]. Copy number changes in a variety of can-
cers – and to a lesser extent, premalignant lesions – have
been detected using this method [46-56]. While CGH
provides a profile of the entire genome, the resolution is
limited and therefore it is difficult to determine the iden-
tity of specific gene alterations. CGH is often used in con-
junction with FISH in order to fine map alterations to the
gene level. As CGH has become a more widely used
method, profile databases have been assembled for public
access (see Table 1).
Cytogentic analysis Figure 2
Cytogentic analysis. Panel A shows an image of fluorescent in situ hybridization. The metaphase chromosome spread is 
hybridized with two locus specific probes labeled with FITC (green) and SpectrumRed (red). Panel B Spectral karyotype 
(SKY) analysis of immortalized human prostate epithelial cells. The line was derived from cells previously described [18]. 
Images provided by Dr. J. Squire.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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Schematic representation of randomly amplified polymorphic DNA PCR analysis of tumor DNA Figure 3
Schematic representation of randomly amplified polymorphic DNA PCR analysis of tumor DNA. Panel A 
shows chromosome with multiple binding sites for selected primers (red arrows). Panel B is a representation of a given locus 
in six different patients. Patient 1 contains both primer sites, patients 2, 4, and 5 contain neither sites, and patients 3 and 6 con-
tain only one of the primer sites. Solid line represents normal chromosome, while the dotted line represents regions of chro-
mosomal loss. Panel C displays the DNA fingerprints for paired normal and tumor DNA from these six individuals. The blue 
bands correspond to fragments indicated in Panel B.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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Array-based CGH
Until recently, localized deletion mapping using micros-
atellite markers has represented the highest resolution
method available to identify potential tumor suppressor
genes. However, new approaches based on the use of
genomic microarrays have been developed. To achieve
higher resolution, Pollack et al. made use of cDNA micro-
arrays for analyzing genomic DNA derived probes
[57,58]. However this approach is hampered by subopti-
mal hybridization which arises because the genomic DNA
probe that is used has introns that are absent in the spot-
ted cDNA target. As mentioned above, the recent develop-
ment of SNP arrays has greatly facilitated deletion
detection, though the resolution of SNP arrays is currently
limited to approximately 10,000 SNPs. One would expect
that only a subset of these loci will be informative (heter-
ozygous). Another technology called representational oli-
gonucleotide microarray analysis (ROMA) provides a
means of detecting genetic alterations in cancer tissue
using a high density oligonucleotide array to profile sub-
tractive hybridization products generated through repre-
sentational differential analysis [59,60].
Complementary to these array-based CGH techniques,
bacterial artificial chromosome (BAC) array CGH allows
the detection of segmental copy number changes [45,61].
BAC array CGH is similar to conventional chromosomal
CGH except that it uses segments of human DNA as
hybridization targets instead of a metaphase spread of
chromosomes [45,61,62] (Fig 4). Hybridization onto
such arrays overcomes the low resolution that limits con-
ventional CGH. As with conventional CGH, total
genomic DNA from a tumor and a normal cell population
are differentially labeled and co-hybridized onto an array.
The ratio of the fluorescence intensities on each DNA spot
on the array is proportional to the copy number of the cor-
responding sequence.
High resolution arrays allow for the delineation of ampli-
fication and deletion boundaries in a single experiment.
These arrays have been instrumental in detailed analysis
of specific chromosomal regions [42,63-68]. High resolu-
tion analysis of entire chromosome arm for segmental
copy number alterations is made possible with whole
chromosome or chromosome arm BAC arrays [69-71].
The application of this technology for genome-wide pro-
filing was first described by Snijders et al., who used 2460
marker BACs and P1 clones to generate an array with
clones positioned at ~1.4 Mbp intervals [72]. Arrays of
similar resolution have been reported by other groups
[73,74]. This technology has been applied to analyze cell
lines and tumors from lymphoma, bladder, breast, pros-
tate, and kidney [75-80].
Further advancement of this technology to tiling resolu-
tion of the whole genome has eliminated the need for
inferring continuity between marker BACs. This was
achieved by using an ordered set of 32,433 BAC clones
that provide full coverage of the genome, allowing the
profiling of the entire genome in a single experiment
[61,81,82] (Fig 5).
Digital karyotyping
Digital karyotyping is a genome wide approach for identi-
fying copy number alterations [83]. This technique
involves the isolation and enumeration of short sequence
tags from specific genomic loci, namely tags adjacent to
Sac I restriction enzyme cut sites throughout the genome.
Digital enumeration of the tags at intervals along each
chromosome reflects DNA content. The concept behind
this DNA profiling technique is analogous to that of serial
analysis of gene expression (SAGE) described below [84],
except that the DNA tags concatenated for sequence anal-
ysis are derived from fragmented genomic DNA rather
than from a cDNA population. The sensitivity and specif-
icity of digital karyotyping depends on the combination
of mapping and fragmenting enzymes employed as well
as the number of tags sampled. The identification of high-
copy-number amplifications can be detected with fewer
tag counts.
Expression profiling
Ultimately, the genome-wide search for oncogenes and
tumor suppressors will require the integration of both
genomic and expression analysis approaches. Integration
of genetic and gene expression data will validate the can-
didate genes in regions of DNA alteration as well as high-
light the downstream effects.
Microarrays
The two main types of microarrays are cDNA microarrays
and oligonucleotide microarrays [85,86]. cDNA microar-
rays have PCR-generated "target" cDNAs deposited onto
glass whereas oligonucleotide microarrays are manufac-
tured using either a photolithographic process that
directly synthesizes them on the glass slide or deposition
of oligonucleotides onto glass slides [87,88]. Both types
of microarray are hybridized with cDNA samples derived
from tissues of interest to assess changes in expression lev-
els. After competitive hybridization of the cDNA samples,
differentially labeled with dyes such as Cyanine 3 and
Cyanine 5, the slides are washed to remove unspecific
binding and then scanned to determine the relative inten-
sities of each channel. Normalization of the samples
allows for differences in labeling and detection efficien-
cies so that the two datasets can be compared [89].
Approximately a quarter of microarray-related literature
pertains to cancer, with tumor and cell line transcriptomeMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
Page 8 of 23
(page number not for citation purposes)
Principle of array CGH Figure 4
Principle of array CGH. This figure shows the steps in BAC array CGH. (A) BAC clones are selected from a physical map of 
the genome. (B) DNA samples are extracted from selected BAC clones and their identity is confirmed by DNA fingerprinting 
or sequence analysis. (C) A multi-step amplification process generates sufficient material from each clone for array spotting. 
Each clone is spotted in replicate onto a solid support. (D) Reference DNA and test DNA are differentially labeled with cya-
nine 3 and cyanine 5 respectively. (E) The two labeled products are combined and hybridized onto the spotted slide. (F) Images 
from hybridized slides are obtained by scanning in two channels. Signal intensity ratios from individual spots can be displayed as 
a simple plot (G) or by using more complex software such as SeeGH, which can display copy number alterations throughout 
the whole genome (H) [82].Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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SeeGH display of whole genome array comparative genomic hybridization Figure 5
SeeGH display of whole genome array comparative genomic hybridization. SeeGH translates spot signal ratio data 
from array CGH experiments to give high resolution chromosome profiles (see Fig 4). Signal ratios are plotted as a log2 scale. 
This figure shows a whole genome profile of a squamous non-small cell lung carcinoma. Vertical green and red lines are scale 
bars indicating log2 ratios. Copy number losses are indicated by a shift in ratio to the left of zero, while gains are reflected by a 
shift to the right. Red and green arrows highlight examples of copy number deletions or gains respectively.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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profiling providing numerous insights into disease [90].
The development of the "lymphochip" cDNA microarray
and other cDNA and oligonucleotide arrays has allowed
the subclassification of many disease types including lym-
phoma, leukaemia, and cancers of the breast and lung
[91-100]. Analysis of small specimens, such as those
derived from premalignant tissue, has been facilitated by
the introduction of RNA amplification methods where
cDNA is linearly amplified, thus preserving the composi-
tion of the original RNA population [101,102]. This anal-
ysis of premalignant lesions has led to the discovery of
new biomarkers for determining prognosis and new tar-
gets for treatment. Frequently used microarray databases
are listed in Table 1.
Serial analysis of gene expression
Unlike microarray technology, which focuses analysis to
only those cDNAs represented on a chip, Serial Analysis of
Gene Expression (SAGE) provides an unbiased profile of
the transcriptome by taking a raw count of sequence tags,
each representing a transcript in an RNA population [84].
The tag count is accomplished through the creation and
quantification of concatenated tags generated from tissue
mRNAs [103]. (Figure 6 summarizes the steps of SAGE
library construction) Absolute quantification of the tran-
scriptome allows the creation of gene expression profiles
that can subsequently be compared against profiles from
other cell types. The longSAGE variation of the SAGE pro-
tocol allows more specific tag mapping, notably to cDNAs
but also to genomic sequence [104]. The microSAGE pro-
tocol, on the other hand, reduces the amount of RNA
required for library construction and therefore facilitates
examination of the early stages in carcinogenesis
[105,106]. There are a number of web resources for SAGE
(see Table 1). SAGEnet provides multiple protocols, while
SAGEmap and SAGE Genie provide analysis tools and
databases [107,108].
SAGE-based research to identify cancer markers has been
conducted for a variety of primary cancers and cell lines,
including breast, kidney, prostate, liver, lung, gastric,
colorectal, and pancreatic cancer [109-128]. In a few of
these instances, such as the work on breast cancer by Por-
ter et al., libraries have been generated for early his-
topathological stages of cancer that demonstrate
expression profiles distinct to each stage [108,114,127].
These authors suggested that some of the observed gene
expression changes tied to progression through the in situ
stages of disease were likely involved with cell growth, dif-
ferentiation, and survival.
Quantitative PCR
Whole genome profiling approaches, such as SAGE and
microarrays, yield candidate genes that require verifica-
tion. Given that biological specimens are often limited in
size, traditional Northern blot analysis may not always be
possible. Reverse-transcriptase polymerase chain reaction
(RT-PCR) provides semi-quantitative assessment of
relative abundance of specific transcripts using gene-spe-
cific primers [129]. Real time RT-PCR measures product
amount after each cycle of amplification based on associ-
ation of fluorescence to the amount of DNA accumulated
during the PCR [130-133]. Three common real-time
approaches are SYBR Green® staining, the TaqMan® sys-
tem, and the molecular beacon system [134]. In the SYBR
Green® method, fluorescent DNA dye that is bound non-
specifically to double-stranded DNA is measured to quan-
tify the accumulation of PCR products. In the Taqman®
system, a fluorescence resonance energy transfer (FRET)
oligonucleotide probe complementary to the target
sequence is used as the reporter system. The fluorescence
of the reporter molecule at the 5' end of the oligonucle-
otide is interfered with by a quencher molecule at the 3'
end. When strand synthesis occurs in PCR, the nuclease
activity of Taq polymerase degrades the FRET probe and
releases the reporter from the quencher, producing fluo-
rescence. In the Molecular Beacon method, the 3'
quencher and 5' reporter of FRET probes initially exhibit
no fluorescence because the oligonucleotide forms a hair-
pin loop that brings these two factors into close proximity.
Binding of the probe at a target sequence separates the two
fluorochromes, allowing the reporter to fluoresce.
Immunohistochemistry, tissue microarrays, and proteomic 
approaches
Basic immunohistochemical (IHC) techniques, when
applied to tissue microarrays (TMA), allow for high
throughput analysis of multiple tissues [135-137]. In the
construction of TMAs, core samples taken from multiple
archival specimens are re-embedded in a paraffin block so
that each section of the TMA would contain multiple sam-
ples for parallel analysis [138]. Similarly, cytology micro-
arrays, with cell suspensions spotted in an array format,
facilitate parallel analysis of intact cells [139].
While IHC examines individual targets, proteomic
approaches aim to assess global changes at the protein
level [8,140]. For more than a quarter century, two-
dimensional polyacrylamide gel electrophoresis has been
a commonly used method for displaying the proteome
[141]. This approach separates proteins based on
isoelectric focusing (pI) and size (polyacrylamide gel elec-
trophoresis). A recently developed method for resolving
proteins is isotope-coded affinity tagging (ICAT) which
allows quantitative analysis of paired protein samples
through the use of stable isotope labeling [142]. Isotopic
tags covalently bind cysteine residues within a protein.
Tagged proteins are separated and identified by liquid
chromatography and mass spectrometry. An assessmentMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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Serial analysis of gene expression (SAGE) library construction Figure 6
Serial analysis of gene expression (SAGE) library construction. This figure shows the steps in SAGE profiling. (A) An 
RNA population is reverse transcribed to cDNAs using oligo-T primers attached to magnetic beads. (B) cDNAs are collected 
and digested with the restriction endonuclease Nla III. (C) Linkers containing sequence recognized by BsmF I are ligated to the 
digested cDNAs. Sequence tags are released from the beads by BsmF I digestion (BsmF I cuts at a fixed distance downstream 
from its recognition site). (D) Released DNA tags are ligated together to form ditags. (E) Ditags are amplified and then digested 
with Nla III to remove the linkers. (F) Ditags are ligated together to form a concatemer which is then clones into a plasmid vec-
tor to generate a SAGE library. The identity and abundance of tags is deduced from DNA sequence analysis of plasmid clones 
of concatemated ditags. (G) Relative abundance of gene expression – between genes within the same RNA population or 
between samples – is deduced by counting sequence tags. Diagrams provided by Dr. K. Lonergan.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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of these two methodologies was provided by Patton et al.
[143].
In contrast to gel electrophoresis, mass spectrometry
assesses protein size by time of flight (TOF) analysis
[144,145]. A technique that incorporates this approach is
surface-enhanced laser desorption/ionization (SELDI)-
TOF, an affinity-based method in which proteins adsorb
to a given chemically modified surface and, subsequently,
the bound proteins are resolved by TOF analysis
[146,147]. This technique is commonly used for detecting
disease-associated proteins in cell lysates as well as serum.
Recently, high throughput proteomic approaches have
been used for identifying protein interactions with other
proteins, nucleic acids, lipids, antibodies, and drugs.
These approaches include protein array-based and phage
display-based methodologies. Cell lysates or protein sam-
ples are differentially labeled and competitively hybrid-
ized to individual protein targets arrayed on a small
surface. Signal intensity ratios are used to calculate the rel-
ative abundance of a given molecule. Commercially avail-
able antibody microarrays have immobilized selected
antibodies targeted against components of known cellular
pathways such as signal transduction, cell cycle regula-
tion, gene transcription, or apoptosis [148].
Proteins may also be displayed on the surface of bacteri-
ophage, serving as an alternative to protein arrays for high
throughput screening [149-151]. In this system, cDNA
libraries are inserted into vectors that generate fusion
products with a bacterial phage coat protein. These recom-
binant proteins are expressed on the surface of the bacte-
riophage and can be screened for interactions with
proteins of interest.
Gene silencing and overexpression
Methylation
Epigenetic changes may alter gene expression. In general,
they are heritable and do not arise due to alterations of
DNA sequence [152]. Methylation is the best character-
ized epigenetic change, typically occurring at CpG dinu-
cleotides within the mammalian genome [153]. CpG
dinucleotides are commonly found in promoter regions,
in "CpG islands" which are long portions of DNA with
high GC content. With the exception of the X chromo-
some, CpG residues in promoter regions are typically
unmethylated [154,155]. Methylation occurs by the
attachment of a methyl group to C5 of the cytosine resi-
due after DNA replication has occurred, resulting in the
loss of gene expression. The relative amount of methyla-
tion can vary, a decrease termed hypomethylation and an
increase known as hypermethylation.
Methylated DNA can be distinguished from unmethyl-
ated DNA by virtue of resistance to 1) methylation sensi-
tive restriction enzyme digestion and 2) bisulfite
treatment. In the first case, isoschizimers such as Hpa II
and Msp I (which recognize CCGG) and Xma I and Sma I
(which recognize CCCGGG) are often used to detect
methylation, since cleavage by Hpa  II and Xma  I are
impaired by internal cytosine methylation of the recogni-
tion sequence. This distinguishing feature is the basis of
global methylation detection methods such as restriction
landmark genomic scanning (RLGS) of CpG island
methylation and methylation target arrays [154,156-159].
In methylation target arrays a multitude of CpG islands
are spotted onto an array and hybridized with probes gen-
erated by linker-mediated PCR-amplification of sample
DNA pre-digested with a methylation-specific enzyme
[160-162]. Methyl-CpG binding proteins can be used to
identify the unique distribution of CpG islands by using
chromatin immunoprecipitation [163]. Methylated DNA
bound to these proteins serves to identify novel targets of
epigenetic inactivation in human cancer. Localization of
these targets can be achieved by hybridization to CpG
island microarrays or through CGH. Bisulfite treatment of
DNA causes selective deamination of cytosine to uracil
[164]. However, in contrast to cytosine, 5-methyl-cytosine
does not react with bisulfite, hence oligonucleotide prim-
ers can be tailored to recognize altered or unaltered
sequence in order to distinguish unmethylated and meth-
ylated targets in a methylation-specific PCR assay.
With respect to the progression of cancer, the genetic
changes associated with disease development are often
accompanied by significant changes in methylation state
[152]. The idea that epigenetic changes can be a mecha-
nism for altering gene expression and driving tumorigen-
esis has been supported by recent work, examples
including work on 14-3-3σ and CCND2 in breast cancer,
p16INK4A and RASSF1A in lung cancer, and HPP1 and
SFRP1 in colorectal cancer [165-170].
Deducing function of novel genes
Cell models
Cell culture models are often used to deduce gene func-
tion through the introduction of a foreign gene or by dis-
ruption of endogenous gene function, thereby creating a
new phenotype or altering cell behaviour.
A new approach for disrupting gene function is RNA inter-
ference (RNAi). This method targets specific genes by way
of post-transcriptional gene silencing. The natural func-
tion of RNAi is thought to be protection of the genome
against invasion by mobile genetic elements such as trans-
posons and viruses, which produce aberrant RNA or
dsRNA in the host cell when they become active [171].
Efforts to develop an RNAi microarray will ultimatelyMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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allow for knockdown analysis of gene function to be
undertaken on a genome-wide scale [172,173].
Animal models
Animal models serve two broad functions in terms of
identifying and characterizing genes involved in cancer
and cancer progression. First, sequence homology
between known animal genes and previously unidentified
human genes allows for speculation as to the gene's func-
tion in humans. This is possible because there are an
increasing number of whole genome sequences available
for a variety of animals (e.g. Fugu,  Drosophila, mouse,
chimpanzee) [174-177]. Second, animals serve as func-
tional models for cancer, allowing researchers to assess
the effects of gene disruption, treatment regimes, and dis-
ease progression. Mammalian models are expected to
more closely mimic the intricacies of human conditions
[178]. The expansive body of literature pertaining to
murine malignancy and the completion of the mouse
genome sequence makes the mouse the leading model for
cancer gene discovery [179,180].
Initial efforts to examine cancer genetics in the mouse
involved incorporation of embryonic stem (ES) cells con-
taining mutated forms of a gene of interest into a develop-
ing mouse [181,182]. Conditional mutants allow spatial
and temporal control over the expression of the
introduced genotypic alteration, an example being the
Cre-lox system [182,183]. Briefly, this system involves the
generation of parallel lines of mice, one having been
manipulated to have the gene of interest flanked by P1
bacteriophage loxP sites and the other having the Cre
recombinase expressed under the control of a tissue-spe-
cific promoter. When these lines are crossed, the gene
book-ended by loxP sites is excised in that tissue where
Cre is expressed, thereby disrupting expression of the gene
of interest and allowing researchers to assess its role in
tumor development in that tissue. There are numerous
variations on this technique currently in use and the Cre-
lox system has been widely applied in cancer progression
research [184,185].
Current cancer progression models
The use of genome-wide analysis has resulted in the dis-
covery of genes involved in cancer progression. This sec-
tion summarizes the cumulative information pertaining
to the genetic alterations and gene expression changes
associated with the progressional stages in four major can-
cer types.
Breast cancer
Histopathological stages of the most common form of
breast cancer include atypical ductal hyperplasia (ADH),
ductal carcinoma in situ (DCIS), and invasive ductal carci-
noma [3]. Inherited alterations at the BRCA1 or BRCA2
loci can predispose individuals to breast cancer, the his-
tology in these cases differing from that seen in sporadic
disease [186,187]. Altered expression of the FHIT tumor
suppressor locus is common in many breast cancer types,
especially in individuals carrying BRCA2 mutations [188].
Recent gene expression profiling studies have served to
identify a genetic basis for the disease stages listed above
[3,53,100,114,127,189,190]. SAGE and microarray data
have demonstrated that relative expression of genes
within the transcriptome vary from stage to stage, with
some of the genes being expressed solely in a specific
stage. Correlation of expression changes between multiple
cases has led to the characterization of prognostic biomar-
kers [97,98,187,191-195]. Furthermore, proteomic stud-
ies have identified additional changes in DCIS not
detected by nucleic acid-based assays [140,196]. Methyla-
tion changes driving breast cancer progression have been
identified using both high throughput techniques and
more established techniques (e.g. methylation-specific
PCR) [113,162,166,167,197-200]. This has lead to the
discovery of epigenetic changes that correlate to disease
outcome and therefore have strong prognostic value.
Figure 7 provides a summary of those genes and chromo-
somal regions implicated in breast cancer progression.
Prostate cancer
Prostate cancer is multifocal and heterogeneous, meaning
that benign, premalignant, and malignant tissues coexist
within the same patient [5]. The prostate cancer progres-
sion model suggests that normal prostatic epithelium
changes to prostatic intraepithelial neoplasm (PIN),
which in turn becomes localized invasive cancer, meta-
static, and, finally, hormone refractory disease with
increasing severity reflected in a higher Gleason grade
[201,202]. The hormone refractory stage occurs after
metastasis, when patients cease to respond to hormone
therapy and quickly succumb to the disease [203]. Both
conventional and high throughput techniques have been
employed to assess the progression of prostate cancer in
terms of chromosomal instability and methylation [203-
210]. Most genes that have been implicated in prostate
cancer development have been identified through linkage
analysis. Brothmann et al. summarized cytogenetic and
molecular genetic alterations associated with hereditary
and sporadic prostate cancer, as well as epigenetic changes
[201]. With new technology, such as LCM, it is now pos-
sible to procure isolated populations of cells to deduce
somatic events. In addition, cDNA microarray and SAGE
technologies have elucidated gene expression changes tied
to prostate cancer progression at each histopathological
stage [202,211-214]. These same technologies have been
used to identify potential biomarkers, taking advantage of
correlation between the expression of specific genes and
Gleason score to generate a prognostic model for patients
that have undergone prostatectomy based solely on geneMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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Progression model of ductal breast cancer Figure 7
Progression model of ductal breast cancer. Histopathological stages of the most common form of breast cancer include 
atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma. This figure highlights the 
changes that occur in breast cancer throughout the histopathological stages of the disease.
Progression model of prostate cancer Figure 8
Progression model of prostate cancer. The prostate cancer progression model suggests that normal prostatic epithelium 
changes to prostatic intraepithelial neoplasm (PIN), which in turn becomes localized invasive cancer, metastatic, and, finally, 
hormone refractory disease with increasing severity reflected in a higher Gleason grade. This figure outlines the changes that 
occur in the progression of prostate cancer.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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expression data [215]. Integration of gene expression pro-
files with tissue microarray data has allowed multiplex
assessment of biomarkers for diagnostics and prognostics
in prostate cancer [216,217]. Those genetic, epigenetic,
and chromosomal alterations that have been character-
ized for prostate cancer are shown in Figure 8.
Lung cancer
Pathogenesis of lung cancer is thought to differ for small
cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC) [218]. Classification of lung cancer subtypes is
possible based solely on differential expression patterns
[94-96,219-223]. Analysis of gene expression, methyla-
tion, and chromosomal changes in lung cancer have
served to better shape the existing lung cancer progression
model [37,167,219,220,224-236]. Disease progression is
best characterized in bronchial squamous cell carcinoma,
a NSCLC subtype where normal epithelium develops
hyperplasia or metaplasia, followed by varying degrees of
dysplasia, and then carcinoma in situ and invasive cancer
[2,237-241]. Alterations on chromosome 3p followed by
alterations on 9p are believed to be the earliest genetic
events to occur in the progression of the disease [242].
Analysis of the early stages of squamous cell carcinoma
has been facilitated by the development of fluorescence
bronchoscopy technology (e.g. the LIFE-Lung device)
allowing the detection and capture of minute lesions
[243,244] (Fig 9). hTERT, located on chromosome 5p, has
also been studied extensively in lung cancer [226]. The
expression pattern for hTERT has been reported to be
slightly increased in the early premalignant stages of
development and gradually increase as the lesion
becomes more severe [226,245]. Figure 10 shows the
genetic alterations understood to drive progression.
Colorectal cancer
Colorectal cancer typically progresses from normal epi-
thelium through dysplasia and adenoma stages to carci-
noma  in situ and finally to invasive cancer [246,247].
Genetic instability is a hallmark of colorectal cancer; mic-
rosatellite instability (MIN) is attributed to DNA mis-
match repair genes, whereas chromosomal instability
(CIN) is characterized by gross chromosomal changes
arising during cell division and commonly involves APC
and  β-catenin mutations [248-250]. cDNA microarray
analysis has revealed different gene expression patterns
for cell cycle regulation and DNA repair genes in colorec-
tal cancer cell lines characterized by CIN or MIN [251].
Furthermore, gene expression profiling with SAGE, oligo-
nucleotide arrays, and cDNA microarrays has been
applied to identify staging and prognostic markers
[112,118,252-259]. Those genes implicated are typically
involved with cell cycle control, apoptosis, angiogenesis,
and transcription machinery. Figure 11 details those alter-
ations understood to drive tumorigenesis in the colorectal
region.
Conclusion
Advances in technology have provided the means for a
global look at an increased resolution. Using a global
approach, identification of genetic alterations and gene
expression changes at the early and late stages of cancer
progression is possible. Through the integration of analy-
sis at the level of the genome, transcriptome, and
Fluorescence bronchoscopy Figure 9
Fluorescence bronchoscopy. Panel A shows a white 
light bronchoscopy image obtained using the LIFE LUNG 
device from the upper left lobe of the lung. Panel B shows 
the detection of a carcinoma in situ lesion due to abnormal 
autofluorescence. The lesion is observed as a brownish area 
in a background of green fluorescence. Images provided by 
Dr. S. Lam.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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Progression model of squamous non-small cell lung carcinoma Figure 10
Progression model of squamous non-small cell lung carcinoma. Squamous cell carcinoma of the lung progresses from 
normal, metaplasia, dysplasia, carcinoma in situ to invasive carcinoma. The alterations present in the various stages of the dis-
ease are outlined in this figure.
Progression model of colorectal cancer Figure 11
Progression model of colorectal cancer. Colorectal cancer typically progresses from normal epithelium through dysplasia 
and adenoma stages to carcinoma in situ and finally to invasive cancer. The changes that occur in the progression of colorectal 
cancer are outlined in this figure.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/9
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proteome, key pathways and functions can be defined.
This will give a better understanding of the critical steps
driving disease progression.
Knowledge of causal events driving progression will allow
for a mechanistic basis for subclassification of disease and
provide novel targets for early diagnosis and the creation
of more specific treatment regimens [260].
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